Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy

Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Alan Y., Lin, Chih-Ying, Lin, Chun-Ju, Lai, Chun-Ting, Hsia, Ning-Yi, Lin, Jane-Ming, Tien, Peng-Tai, Meng, Ping-Ping, Ku, Wei-Ning, Chen, Wen-Lu, Tsai, Yi-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784980/
https://www.ncbi.nlm.nih.gov/pubmed/36556905
http://dx.doi.org/10.3390/medicina58121703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784980/
https://www.ncbi.nlm.nih.gov/pubmed/36556905
http://dx.doi.org/10.3390/medicina58121703

Ejemplares similares